Submit Your Feeds

Business News • PR NewsWire • BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients

BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients
BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients

LUND, Sweden, Jan. 28, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces positive interim results from...

View More : https://www.prnewswire.com:443/news-releases/bioinvent-phase-iiia-data-suggest-bi-1206-restores-activity-of-rituximab-in...
Releted News by prnewswire
La asociación de la plataforma EZDRM con el ecosistema de desarrolladores de Huawei brinda una protección de contenido mejorada a los desarrolladores
THC BioMed erhält Kaufauftrag für THC Kiss Gummies von der Provinz British Columbia
GAC Group achieves breakthrough in graphene-based fast-charging battery technology, vehicle model Aion V equipped with the new battery to start production in September
BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients
Omixon y SeqOnce Biosciences amplían AzureSeq-200 CE One-step RT-qPCR para detectar SARS-CoV-2 N501Y
El presidente de Colombia inaugura oficialmente planta de energía fotovoltaica de Trina Solar
Home Sitemap Contact Us
© businessNewsNewsNews.com